Macrophage Plasticity and Polarization Are Altered in the Experimental Model of Multiple Sclerosis.
EAE
chemokines
cytokines
macrophages
multiple sclerosis
toll-like receptors
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
04 06 2021
04 06 2021
Historique:
received:
26
03
2021
revised:
09
05
2021
accepted:
31
05
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
24
9
2021
Statut:
epublish
Résumé
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. MS is characterized by infiltrations of leukocytes such as T and B lymphocytes and macrophages. Macrophages have been identified as major effectors of inflammation and demyelination in both MS and its animal model, experimental autoimmune encephalomyelitis (EAE). However, the activation and heterogeneity of macrophages in MS has been poorly investigated. Thus, in this study, we evaluated M1 and M2 macrophages immunophenotype from EAE and control mice by analyzing over 30 surface and intracellular markers through polychromatic flow cytometry, qRT-PCR, and ELISA assay. We showed that M1 macrophages possessed a higher proinflammatory profile in EAE compared to control mice, since they expressed higher levels of activation/co-stimulatory markers (iNOS, CD40, and CD80) and cytokines/chemokines (IL-6, IL-12, CCL2, and CXCL10), whereas M2 lost their M2-like phenotype by showing a decreased expression of their signature markers CD206 and CCL22, as well as a concomitant upregulation of several M1 makers. Furthermore, immunization of M1 and M2 macrophages with MOG35-55 led to a significant hyperactivation of M1 and a concomitant shift of anti-inflammatory M2 to pro-inflammatory M1 macrophages. Overall, we provide evidence for a phenotypic alteration of M1/M2 balance during MS, which can be of crucial importance not only for a better understanding of the immunopathology of this neurodegenerative disease but also to potentially develop new macrophage-centered therapeutic strategies.
Identifiants
pubmed: 34200023
pii: biom11060837
doi: 10.3390/biom11060837
pmc: PMC8229971
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Brain Pathol. 2015 Nov;25(6):712-23
pubmed: 25495532
J Pathol. 2013 Jan;229(2):176-85
pubmed: 23096265
Immunobiology. 2009;214(7):554-61
pubmed: 19162368
Clin Dev Immunol. 2013;2013:948976
pubmed: 23840244
FEBS Lett. 2011 Dec 1;585(23):3715-23
pubmed: 21854776
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
J Exp Med. 2000 Oct 2;192(7):1075-80
pubmed: 11015448
J Neuroimmunol. 2011 Oct 28;239(1-2):1-12
pubmed: 21889214
J Immunol. 2011 Jul 15;187(2):791-804
pubmed: 21685327
N Engl J Med. 2000 Sep 28;343(13):938-52
pubmed: 11006371
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
Brain Res Brain Res Rev. 2005 Apr;48(2):185-95
pubmed: 15850657
Eur J Immunol. 2008 Feb;38(2):565-75
pubmed: 18203139
Science. 2013 Jan 11;339(6116):156-61
pubmed: 23307732
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Mult Scler. 2011 Jan;17(1):2-15
pubmed: 20813772
Cell Mol Life Sci. 2017 Aug;74(15):2815-2826
pubmed: 28299384
J Neurosci. 2014 Jun 11;34(24):8175-85
pubmed: 24920622
J Neurosci Res. 2005 Aug 1;81(3):363-73
pubmed: 15948188
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11555-60
pubmed: 20534434
Curr Top Med Chem. 2014;14(22):2590-9
pubmed: 25478879
Eur J Immunol. 2008 Dec;38(12):3269-73
pubmed: 19039773
J Neurosci. 2009 Mar 18;29(11):3442-52
pubmed: 19295150
Immunity. 2011 Jan 28;34(1):75-84
pubmed: 21236705
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2764-9
pubmed: 19188597
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
CNS Neurosci Ther. 2012 Nov;18(11):909-17
pubmed: 22994384
Annu Rev Immunol. 2005;23:515-48
pubmed: 15771580
Semin Immunol. 2003 Feb;15(1):23-32
pubmed: 12495638
J Clin Invest. 1999 Jan;103(2):281-90
pubmed: 9916140
J Mol Med (Berl). 1997 Mar;75(3):165-73
pubmed: 9106073
J Neurosci. 2013 Jul 17;33(29):12105-21
pubmed: 23864696
PLoS One. 2013;8(2):e54841
pubmed: 23418431
Nat Immunol. 2007 Sep;8(9):913-9
pubmed: 17712344
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Annu Rev Immunol. 1998;16:111-35
pubmed: 9597126